Oppenheimer analyst Steven Lichtman downgraded Integra LifeSciences (NASDAQ: IART) from Outperform to Perform.The analyst comments "Following an announced delay in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Downgrades

Integra LifeSciences (IART) PT Lowered to $26 at BofA SecuritiesMay 7, 2024 5:38 AM Integra LifeSciences (IART) PT Lowered to $40 at JMP SecuritiesMay 7, 2024 2:25 AM Integra LifeSciences (IART) PT Lowered to $24 at Morgan StanleyMay 6, 2024 11:43 PM Wells Fargo Downgrades Integra LifeSciences (IART) to Equal WeightMay 6, 2024 4:15 PM Form 10-Q INTEGRA LIFESCIENCES For: Mar 31May 6, 2024 4:10 PM Form 8-K INTEGRA LIFESCIENCES For: May 06May 6, 2024 6:17 AM Integra LifeSciences (IART) Reports In-Line Q1 EPS, provides guidanceMay 6, 2024 6:14 AM Integra LifeSciences Reports First Quarter 2024 Financial ResultsMay 6, 2024 6:00 AM